We are developing therapies that, administered just once, have the potential to transform the lives of people with severe genetic and rare diseases and cancer. Our current platform is just the beginning. We are committed to continuing to develop gene therapy technologies and capabilities that have broad potential beyond the core indications.
We are actively seeking collaborators and licensing opportunities in the U.S. and around the world to explore the therapeutic potential of our technologies in new cell types and diseases.
In December 2015, we entered into an exclusive license agreement to research, develop and commercialize chimeric antigen receptor (CAR) T cell therapies using ViroMed’s proprietary humanized antibody to an undisclosed cancer target for solid tumors.
Under the terms of the agreement, ViroMed will provide us exclusive rights to its novel humanized antibody to the target, and we will leverage our proprietary lentiviral gene therapy platform and CAR T capabilities to develop CAR T therapies against the target. Financial terms of the agreement include a $1 million upfront payment and subsequent milestone payments to ViroMed, which together could total over $48 million per licensed product if certain development and regulatory milestones are achieved. ViroMed is also eligible to receive tiered royalties on product sales. bluebird bio will conduct and fund clinical development as well as regulatory and commercial activities.
In June 2016, we entered into a strategic manufacturing agreement with Lonza Houston, Inc., providing for the future commercial production of our Lenti-D™ and LentiGlobin™ drug products.
This agreement follows a successful multi-year clinical manufacturing relationship and provides us with a path to commercial supply including dedicated production suites within Lonza’s state-of-the-art facility. Under this multi-year agreement, Lonza will complete the suite design, construction and validation along with process validation prior to anticipated commercial launch.
In December 2016, we entered into a strategic manufacturing agreement with apceth Biopharma for the future European commercial production of our Lenti-D™ product candidate for cerebral adrenoleukodystrophy and our LentiGlobin™ product candidate for transfusion-dependent β-thalassemia.
Under this multi-year agreement, apceth Biopharma will perform clinical manufacturing, process validation activities and commercial manufacturing for LentiGlobin and Lenti-D drug product to support the treatment of European patients with transfusion-dependent beta thalassemia and cerebral adrenoleukodystrophy, respectively. This agreement follows a successful multi-year manufacturing relationship and provides us with European commercial manufacturing capabilities, including dedicated production suites within apceth Biopharma’s state-of-the-art GMP facility.